PDCD1 and non-small cell lung carcinoma: Since immune checkpoint inhibitors mainly show durable response rates in NSCLC patients, a combinatorial treatment of PD-L1/PD-1 blockade and EGFR-TKIs might be a promising strategy to prolong duration of response and to delay or even prevent resistance [124,125].